DRREDDY.NS Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 май 2024 @ 13:00):

Stats
Объем за сегодня	1.03M
Средний объем	404 913
Рыночная капитализация	964.14B
EPS	INR0 ( 2024-05-06 )
Дата следующего отчета о доходах	( INR76.04 ) 2024-07-23
Last Dividend	INR40.00 ( 2023-07-11 )
Next Dividend	INR0 ( N/A )
P/E	17.30
ATR14	INR11.20 (0.19%)

Объем Корреляция

Длинно: -0.76 (moderate negative)

Кратко: -0.83 (strong negative)

Signal:(43.581) Neutral

Dr. Reddy's Laboratories Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Dr. Reddy's Laboratories Корреляция - Валюта/Сырье

0.83
( strong )

0.53
( weak )

-0.86
( strong negative )

0.73
( moderate )

-0.18
( neutral )

-0.60
( weak negative )

Dr. Reddy's Laboratories Финансовые показатели

Annual	2023
Выручка:	INR279.16B
Валовая прибыль:	INR163.61B (58.61 %)
EPS:	INR334.02

FY	2023
Выручка:	INR279.16B
Валовая прибыль:	INR163.61B (58.61 %)
EPS:	INR334.02

FY	2022
Выручка:	INR245.88B
Валовая прибыль:	INR169.30B (68.86 %)
EPS:	INR271.43

FY	2022
Выручка:	INR214.39B
Валовая прибыль:	INR113.84B (53.10 %)
EPS:	INR142.08

Financial Reports:

No articles found.

Dr. Reddy's Laboratories Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR60.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR40.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Dr. Reddy's Laboratories Dividend Information - Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 7.29 - Increase likely (45.83%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR2.50	2003-08-08
Last Dividend	INR40.00	2023-07-11
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	23	--
Total Paid Out	INR363.00	--
Avg. Dividend % Per Year	0.62%	--
Score	3.8	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	7.29
Div. Directional Score	9.40	--

Next Divdend (Est)
(2024-07-01)

INR42.96 Estimate 3.12 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.80

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR40.00	1.93%
2019	INR20.00	0.77%
2020	INR25.00	0.87%
2021	INR25.00	0.48%
2022	INR60.00	1.24%
2023	INR40.00	0.94%
2024	INR0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SHARDAMOTR.NS	Dividend Knight	2023-09-18	Annually	9	0.90%
MANAKALUCO.NS	Dividend Junior	2023-08-22	Insufficient data to determine frequency	2	0.08%
GICHSGFIN.NS	Dividend Knight	2023-08-25	Annually	23	1.62%
ARVINDFASN.NS	Dividend Junior	2023-09-01	Insufficient data to determine frequency	2	0.10%
PITTIENG.NS	Dividend Junior	2023-08-11	Annually	18	0.51%
JAYAGROGN.NS	Dividend Knight	2023-07-07	Annually	23	1.14%
CYBERTECH.NS	Dividend Knight	2023-09-22	Annually	18	0.77%
SOTL.NS	Dividend Knight	2023-09-22	Annually	23	1.23%
MINDACORP.NS	Dividend Knight	2023-07-21	Annually	12	0.38%
GRPLTD.NS	Dividend Junior	2023-07-28	Annually	10	0.46%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.199	1.500	6.01	9.02	[0 - 0.5]
returnOnAssetsTTM	0.144	1.200	5.21	6.25	[0 - 0.3]
returnOnEquityTTM	0.213	1.500	8.75	10.00	[0.1 - 1]
payoutRatioTTM	0.119	-1.000	8.81	-8.81	[0 - 1]
currentRatioTTM	2.58	0.800	2.09	1.669	[1 - 3]
quickRatioTTM	1.684	0.800	4.80	3.84	[0.8 - 2.5]
cashRatioTTM	0.0740	1.500	-0.700	-1.050	[0.2 - 2]
debtRatioTTM	0.0517	-1.500	9.14	-10.00	[0 - 0.6]
interestCoverageTTM	59.84	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	271.47	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	106.71	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.0714	-1.500	9.71	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.586	1.000	3.57	3.57	[0.2 - 0.8]
operatingProfitMarginTTM	0.240	1.000	7.21	7.21	[0.1 - 0.6]
cashFlowToDebtRatioTTM	2.26	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.720	0.800	8.53	6.82	[0.5 - 2]
Total Score				11.51

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	17.32	1.000	8.35	0	[1 - 100]
returnOnEquityTTM	0.213	2.50	9.19	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	106.71	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.691	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	271.47	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.119	1.500	8.81	-8.81	[0 - 1]
pegRatioTTM	1.389	1.500	4.08	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.162	1.000	8.45	0	[0.1 - 0.5]
Total Score				7.29

Dr. Reddy's Laboratories Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.